Cautious Outlook for Akoya Biosciences Amidst Competitive Pressures and Promising Long-Term Potential

Morgan Stanley analyst Tejas Savant maintained a Hold rating on Akoya Biosciences (AKYA – Research Report) today and set a price target of $1.14.

Tejas Savant has given his Hold rating due to a combination of factors influencing Akoya Biosciences’ current and future performance. The company’s revenue estimates for 2025 and 2026 have been revised downward, reflecting a cautious outlook in the near term. This adjustment is partly due to the macroeconomic environment, including policy headwinds and competitive pressures from better-capitalized peers, which may impact Akoya’s market strategy and development plans.
Despite these challenges, Akoya Biosciences holds promising long-term potential, particularly with its innovative platforms like the PhenoCycler-Fusion system and PhenoImager-HT. These platforms, along with the launch of PhenoCode Panels, position the company well to meet the growing demand in the spatial biology market. Additionally, the outstanding merger bid and interest from a third party provide a safety net for the stock, supporting the Hold recommendation.

In another report released on May 19, Canaccord Genuity also reiterated a Hold rating on the stock with a $1.08 price target.